Pikralida is a fast-growing biotechnology company that combines research and development (R&D) activities with Contract Research Organization (CRO) services, creating a unique hybrid business model. We specialize in discovering and developing innovative therapeutic solutions. Currently, our flagship project is the development of PKL-021, an active inhibitor of matrix metalloproteinases (MMPs). 

Our R&D laboratories in Poznań and Warsaw provide a modern infrastructure for conducting advanced research projects. In Poznań, we focus on the development of pharmaceutical formulations, while in Warsaw, we specialize in the manufacturing processes of active substances. Our interdisciplinary team consists of 20 experienced scientists, over 30% of whom hold a PhD, ensuring broad expertise and the capability to execute the most demanding projects. 

As a clinical-stage company, we support our clients at every stage of their research activities, offering comprehensive CRO services – from study design and execution to preparing the necessary documentation. With in-depth knowledge of regulatory requirements and extensive experience in preclinical and clinical research, we manage projects with a full understanding of the drug development process. Our approach not only shortens the time to market but also increases project efficiency, driving innovation in medicine and pharmaceuticals. 

In our laboratories in Poznań and Warsaw, we conduct advanced research projects, combining world-class infrastructure with the interdisciplinary expertise of our team. Thanks to our well-adapted facilities, we effectively support both the development of our own therapies and the execution of our partners’ projects within our CRO services.